Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

PHOENIX, Oct. 14, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of $130 million in growth capital to Candel Therapeutics, Inc. (Nasdaq: CADL) ("Candel"), a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer.

Read more at prnewswire.com